

	Stakeholder categories	Individuals working on or with experience in:	Rationale of their contribution:
Delphi 1 <i>Research Priorities</i>	Research Funders (public and/or private)	* Responsibility in management and/or design of Public funding schemes for research (government agencies, public organizations, funding programs at universities, etc.). * Responsibility in management and/or design of Private funding schemes for research (research and development departments in companies, scientific societies, charities and other private organizations, etc.).	<i>views on how patient engagement fits into their decisions and processes to set priorities for the research to be funded. Suitability of engagement practices in place. How it shapes results</i>
	Regulators	Health authority at national or regional level (end user of evidence to inform its decision making)	<i>views on the impact of patient engagement on the research agenda and how it affects the usability of research findings for adoption and reimbursement decisions</i>
	HTA Bodies	Health Technology Assessment	<i>views on how patient engagement in research priorities affects the suitability of available evidence to assess new drugs</i>
	Academics, researchers	Conducting and/ or managing research	<i>views on how patient engagement affects their research agenda</i>
	Healthcare Professionals	Healthcare providers (healthcare managers (primary care and hospital), clinicians/health professionals associations).	<i>views on how patient engagement in research priorities affects the availability and adoption of new drugs</i>
	Patients/ Patient organizations	Participating (in the role of patient) in research priorities setting, research projects, research design, etc.	<i>views on how patient engagement fits into funders' decisions and processes to set research priorities. Suitability of engagement practices in place</i>
Delphi 2 <i>Clinical Trials</i>	Clinical trials promoter (pharma companies or else)	Designing, preparing and conducting clinical trials	<i>views on how patient engagement fits into their decisions and processes to conduct clinical trials</i>
	Academics, researchers	Designing, preparing and conducting clinical trials	<i>views on how patient engagement affects their research agenda and the quality of findings</i>
	Healthcare professionals	Designing, preparing and conducting clinical trials	<i>views on how patient engagement affects new drugs availability and adoption</i>
	HTA bodies	Clinical trials Health Technologies Assessment	<i>views on how patient engagement affects the suitability of available evidence to assess new drugs</i>
	Regulators	Clinical trials regulation	<i>views on how patient engagement in design and analysis of clinical trials affects the quality (including ethics-wise) and usability of findings</i>
Patients/ Patient organizations	Participating (in the role of patient) in designing, preparing and conducting clinical trials.	<i>views on how patient engagement fits into researchers and funders' decisions and processes to design clinical trials. Suitability of engagement practices in place. How it shapes quality and usability of findings</i>	
Delphi 3 <i>Early Dialogues</i>	HTA bodies	Participating in Early Dialogues	<i>views on how patient engagement fits into early dialogues dynamics. Suitability of engagement practices in place. How it shapes results</i>
	Pharma companies, Industry	Participating in Early Dialogues	<i>views on how patient engagement fits into early dialogues dynamics. Suitability of engagement practices in place. How it shapes results</i>
	Regulators	Health authority at national or regional level (reimbursement decision maker) participating in early dialogues	<i>views on how patient engagement fits into early dialogues dynamics. Suitability of engagement practices in place. How it shapes results</i>
	Patients/ Patient organizations	Participating (in the role of patient) in early dialogues	<i>views on how patient engagement fits into early dialogues dynamics. Suitability of engagement practices in place. How it shapes results</i>

*** Special attention should be paid to having equal number of: Female and male representatives of each categories and of individuals coming from different countries**